AstraZeneca
📋 Case Summary
What happened The MHRA forwarded a complaint from an ex-employee about representative call-frequency targets linked to promotion of Casodex (bicalutamide). Evidence included an AstraZeneca oncology sales/marketing booklet with activity targets and an internal email explaining call-frequency targets. The complainant alleged target doctors were expected to be called on once a month (12 face-to-face calls per year for main targets in 2004 and early 2005). The complainant alleged the “AZpiration” scheme awarded points for call frequency that could be exchanged for prizes, described as an inducement to breach the Code. The complainant alleged pressure and threats via short-term performance measures, described as bullying/harassment to achieve call targets. Additional allegation: an August 2004 meeting (Ashby-de-la-Zouch) was intimidating; however, the meeting was not recorded and there were no speaker notes/transcript. AstraZeneca argued the complaint was closely similar to earlier adjudica
📌 Clauses Breached
15.4,15.9,9.1